Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21139931 | 0.92 | KMO (0.67) | KMODRD2DRD3 | |
| SCHEMBL4213804 | 0.92 | KMO (0.67) | KMODRD2DRD3 | |
| SCHEMBL13406410 | 0.90 | KMO (0.72) | KMODRD2DRD3 | |
| SCHEMBL13406411 | 0.90 | KMO (0.72) | KMODRD2DRD3 | |
| SCHEMBL31311744 | 0.87 | DRD2 (0.55) | KMODRD2DRD3 | |
| SCHEMBL6051833 | 0.84 | KMO (0.96) | KMODRD3KMT2A | |
| SCHEMBL15019437 | 0.84 | KMO (0.90) | KMODRD3KMT2A | |
| SCHEMBL231800 | 0.83 | DRD2 (0.51) | KMODRD2DRD3 | |
| SCHEMBL30488766 | 0.83 | DRD2 (0.51) | KMODRD2DRD3 | |
| SCHEMBL1633310 | 0.83 | KMO (0.71) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3461824-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KMO 2392/4885DRD2 4760/4885DRD3 4605/4885 |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KMO 2392/4885DRD2 4760/4885DRD3 4605/4885 |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | KMO 2392/4885DRD2 4760/4885DRD3 4605/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KMO 2392/4885DRD2 4760/4885DRD3 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.